Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost

Completed

• Conditions: HIV Infections; AIDS; Antiretroviral Therapy; HIV
• Interventions: Behavioral: Control; Behavioral: Intervention

• Registration Number: NCT01645865
• Lead Sponsor: Elizabeth Glaser Pediatric AIDS Foundation

Brief Summary

Although gains have been made in achieving the health-related Millennium Development Goals (MDG), much is still needed in countries affected by high levels of HIV/AIDS. Prevention of mother-to-child transmission (PMTCT) is a cornerstone strategy in reducing infant mortality from HIV. The study will employ a cluster randomized control trial (cRCT) with 26 health facilities randomized to two arms (intervention or control) to determine the effect of mobile phone technology on completion of key PMTCT milestones from antenatal to six weeks postpartum. The study will examine the acceptability, effectiveness, and cost of implementing a PMTCT-focused mHealth strategy among HIV-infected pregnant women, health workers, and male partners.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05
• Study First Submitted: 2012-07-18
• Study First Submitted QC: 2012-07-19
• Study First Posted: 2012-07-20
• Primary Completion: 2014-04
• Study Completion: 2014-04
• Status Verified: 2014-11
• Last Update Submitted: 2014-11-12
• Last Update Posted: 2014-11-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control	Control	-
Intervention	Intervention	-

Primary Outcome Measures

Name	Time	Method
Initiation of Infant prophylaxis, Facility delivery and receipt of results of 6 weeks early infant diagnosis by DNA PCR	~ 6 months
The proportion of women who successfully complete key PMTCT transition points from antenatal to six weeks postpartum.	~ 6 months

Secondary Outcome Measures

Name	Time	Method
Uptake ARV prophylaxis/ART during labor, delivery, and postpartum	~ 6 months
Self-reported maternal adherence to ARV prophylaxis/ART during pregnancy	~ 4 months
Time to initiation of ARV prophylaxis/ART uptake after initial identification of HIV seropositivity within ANC	~ 1 month

Trial Locations

Locations (1)

Elizabeth Glaser Pediatric AIDS Foundation; 🇰🇪 Nairobi, Kenya